Baseline characteristics
| Characteristic . | Patients with AHA (N = 69) . | Controls (N = 69) . | P value for difference . |
|---|---|---|---|
| Age in years, mean (SD, range) | 67 (15, 26-97) | 65 (18, 22-89) | .519 |
| Female, n (%) | 31 (45) | 28 (41) | .731 |
| AHA-associated clinical disorders | |||
| Autoimmune disorders | 12 (17) | 1 (1) | .002 |
| Malignancy | 8 (12) | 10 (14) | .801 |
| Pregnancy | 5 (7) | 1 (1) | .208 |
| Immunosuppressive therapy,∗ n (%) | 4 (6) | 4 (6) | >.999 |
| Corticosteroids | 4 | 2 | |
| Other | 1 | 3 | |
| Inhibitor concentration in BU/mL† | |||
| Median | 15 | 0 | <.0001 |
| IQR | 7.4-71 | 0-0 | |
| Range | 1.1-1448 | 0-0 | |
| Anti-FVIII IgG in AU/mL‡ | |||
| Median | 604 | 4.6 | <.0001 |
| IQR | 237-1608 | 3.0-7.7 | |
| Range | 0.5-51500 | 0.8-19 | |
| Characteristic . | Patients with AHA (N = 69) . | Controls (N = 69) . | P value for difference . |
|---|---|---|---|
| Age in years, mean (SD, range) | 67 (15, 26-97) | 65 (18, 22-89) | .519 |
| Female, n (%) | 31 (45) | 28 (41) | .731 |
| AHA-associated clinical disorders | |||
| Autoimmune disorders | 12 (17) | 1 (1) | .002 |
| Malignancy | 8 (12) | 10 (14) | .801 |
| Pregnancy | 5 (7) | 1 (1) | .208 |
| Immunosuppressive therapy,∗ n (%) | 4 (6) | 4 (6) | >.999 |
| Corticosteroids | 4 | 2 | |
| Other | 1 | 3 | |
| Inhibitor concentration in BU/mL† | |||
| Median | 15 | 0 | <.0001 |
| IQR | 7.4-71 | 0-0 | |
| Range | 1.1-1448 | 0-0 | |
| Anti-FVIII IgG in AU/mL‡ | |||
| Median | 604 | 4.6 | <.0001 |
| IQR | 237-1608 | 3.0-7.7 | |
| Range | 0.5-51500 | 0.8-19 | |
ND, not determined; SD, standard deviation.
Before diagnosis (in patients with AHA) or at the time of sampling (in controls).
Reference value < 0.6 BU/mL. Values below 0.6 BU/mL were reported as zero.
Reference value < 12.8 AU/mL. One out of 69 patients with AHA was negative for anti-FVIII IgG (<12.8 AU/mL) but had anti-FVIII IgM. Two out of 69 controls were positive for anti-FVIII IgG (>12.8 AU/mL) but negative for inhibitor in the NBA.